Table 1

Baseline characteristics of women and men in the study population across the glycemic spectrum

Women (n=5698)Men (n=3803)
Normoglycemia (n=4468)Impaired fasting glucose (n=634)Type 2 diabetes mellitus (n=596)Normoglycemia (n=2753)Impaired fasting glucose (n=570)Type 2 diabetes mellitus (n=480)
Age, mean (SD)63.8 (9.8)67.0 (9.6)68.3 (10.3)62.7 (9.2)64.1 (8.3)65.5 (9.0)
BMI, kg/m2, mean (SD)26.8 (4.3)29.0 (5.0)30.2 (5.2)26.5 (3.3)28.0 (3.6)28.7 (4.4)
Prevalent overweight/obese (BMI ≥25 kg/m2), n (%)2777 (62.2)509 (80.3)508 (85.2)1830 (66.5)468 (82.1)382 (79.6)
Hypertension,* n (%)2392 (53.5)472 (74.4)479 (80.4)1499 (54.4)410 (71.9)387 (80.1)
Hypertension medication, n (%)1184 (26.5)260 (41.0)315 (52.9)607 (22.0)184 (32.3)215 (44.8)
Total cholesterol, mmol/L, mean (SD)5.9 (1.0)5.9 (0.9)5.7 (1.0)5.6 (0.9)5.7 (1.0)5.3 (1.1)
HDL-cholesterol, mmol/L, mean (SD)1.6 (0.4)1.5 (0.4)1.3 (0.4)1.3 (0.3)1.2 (0.3)1.1 (0.3)
Lipid-lowering medication, n (%)628 (14.1)124 (19.6)139 (23.3)366 (13.3)82 (14.4)128 (26.7)
  • P values for all cardiovascular risk factors for both women and men were significant at <0.001.

  • *Hypertension was defined as systolic blood pressure of ≥140 mm Hg and/or diastolic blood pressure of ≥90 mm Hg and/or a current prescription for antihypertensive medication.

  • BMI, body mass index; HDL, high-density lipoprotein.